Last €1.60 EUR
Change Today -0.01 / -0.62%
Volume 0.0
GVC1 On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 3:00 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

genvec inc (GVC1) Snapshot

Open
€1.60
Previous Close
€1.61
Day High
€1.63
Day Low
€1.58
52 Week High
01/27/14 - €3.09
52 Week Low
09/4/13 - €0.16
Market Cap
27.7M
Average Volume 10 Days
230.0
EPS TTM
--
Shares Outstanding
17.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENVEC INC (GVC1)

Related News

No related news articles were found.

genvec inc (GVC1) Related Businessweek News

No Related Businessweek News Found

genvec inc (GVC1) Details

GenVec, Inc. operates as a biopharmaceutical company that uses differentiated and proprietary technologies to create therapeutics and vaccines. The company develops its product candidates through collaborations with various companies and organizations, including Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of various human and animal health concerns. Its development programs address various therapeutic areas, such as hearing loss and balance disorders; and vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, dengue fever, and malaria. The company is also involved in developing vaccines against foot-and-mouth disease in the area of animal health. GenVec, Inc. was founded in 1992 and is based in Gaithersburg, Maryland.

11 Employees
Last Reported Date: 03/28/14
Founded in 1992

genvec inc (GVC1) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: $316.3K
Senior Vice President of Development
Total Annual Compensation: $278.1K
Chief Scientific Officer
Total Annual Compensation: $310.7K
Compensation as of Fiscal Year 2013.

genvec inc (GVC1) Key Developments

GenVec, Inc. Announces Auditor Changes

On June 11, 2014, the Audit Committee of the Board of Directors of GenVec, Inc. dismissed KPMG LLP as the company's independent registered public accounting firm, effective immediately. On June 11, 2014, the Audit Committee approved the engagement of Stegman & Company as its independent registered public accounting firm for the fiscal year ending December 31, 2014.

GenVec, Inc. Reports Unaudited Financial Results for the First Quarter Ended March 31, 2014

GenVec, Inc. reported unaudited financial results for the first quarter ended March 31, 2014. For the quarter, the company reported a net loss of $1.0 million, or $0.07 per basic and diluted share compared with a net loss of $3.0 million, or $0.24 per basic and diluted share for the same period in the prior year. Revenues were $2.1 million, which represents a 77% increase as compared to $1.2 million in the comparable prior year period. The increase in revenue for the three-month period ended March 31, 2014 is primarily attributable to an increase of $1.6 million associated with the hearing loss and balance disorders program. The increase in revenue was a result of the company's achievement of the third milestone under the company's agreement with Novartis. The $2.0 million milestone was triggered by the non-rejection by the FDA of Novartis's IND for CGF166 in the three-month period ended March 31, 2014. This increase was partially offset by a decrease in revenue associated with the company’s development agreements with Novartis and the company's hearing grant, which was completed in 2013, of $0.4 million for the three-month period ended March 31, 2014 as compared to the same period in 2013. Additionally, there were reductions in revenues of $0.3 million with respect to the company's foot-and-mouth disease (FMD) program and $0.4 million resulting from reduced work scope and grant work performed for the company's NIH programs and malaria programs. Operating loss was $0.964 million against $3.054 million a year ago.

GenVec, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the Full Year of 2014

GenVec, Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported revenues of $145,000 against $1,521,000 a year ago. Operating loss was $1,146,000 against $3,170,000 a year ago. Net loss was $887,000 or $0.07 per basic and diluted share against $3,159,000 or $0.24 per basic and diluted share a year ago. For the full year, the company reported revenues of $3,682,000 against $14,353,000 a year ago. Operating loss was $10,294,000 against $14,097,000 a year ago. Net loss was $10,019,000 or $0.77 per basic and diluted share against $14,055,000 or $1.09 per basic and diluted share a year ago. For 2014, the company anticipated cash burn between $5.0 million and $7.0 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GVC1:GR €1.60 EUR -0.01

GVC1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $2.92 USD +0.02
Argos Therapeutics Inc $6.47 USD -0.08
Progenics Pharmaceuticals Inc $5.08 USD +0.03
Vical Inc $1.25 USD -0.03
ZIOPHARM Oncology Inc $3.16 USD -0.10
View Industry Companies
 

Industry Analysis

GVC1

Industry Average

Valuation GVC1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.4x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENVEC INC, please visit www.genvec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.